Biotech company Nutri Pharma has been awarded a patent by the US authorities to protect the composition of its staple soy product. The company, which manufactures many products relying on a soy basis, has also posted higher than anticipated operating costs due to marketing and preparations for future product launches. They also revealed a widening of Q3 pre-tax loss, which has reached NKr9.3m from 1999's figure of NKr0.8m.
Biotech company Nutri Pharma has been awarded a patent by the US authorities to protect the composition of its staple soy product. The company, which manufactures many products relying on a soy basis, has also posted higher than anticipated operating costs due to marketing and preparations for future product launches. They also revealed a widening of Q3 pre-tax loss, which has reached NKr9.3m from 1999’s figure of NKr0.8m.
